An ATF3 Inducer Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease Through the AMPK and PKA Pathways
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262411877 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ching-Feng Cheng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 23142, Taiwan. Hauptthemen laut MEDLINE: Activating Transcription Factor 3, Cyclic AMP-Dependent Protein Kinases, AMP-Activated Protein Kinases, Signal Transduction. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, the collaborative grants from the Tzu Chi Medical Foundation, the Tzu Chi University, and Ac-ademia Sinica.
Abstract (Originalsprache)
Obesity is linked to metabolic dysfunction-associated steatotic liver disease (MASLD), but the molecular mechanisms and effective treatments remain unclear. This study investigated whether ST32db, an inducer of activating transcription factor 3 (ATF3), affects lipid metabolism in MASLD. An in vitro model was established involving the treatment of HepG2 cells with 1 mM oleic acid (OA) with or without 20 µM ST32db. In an in vivo model, C57BL/6 mice were fed a high-fat diet (HFD) for 18 weeks to induce obesity and treated or not with ST32db (1 mg kg−1). ST32db significantly decreased intracellular lipid accumulation in OA-treated HepG2 cells. In these cells, ST32db remarkably decreased mRNA and protein levels of adipogenesis- and lipogenesis-related genes and increased mRNA levels of adipose triglyceride lipase (ATGL), a lipolytic enzyme. In HFD-fed mice, the ST32db treatment significantly decreased the liver weight, serum triglycerides, and fat vacuole and triglyceride accumulation in the liver. Livers from these mice also showed significantly decreased CCAAT/enhancer-binding protein β mRNA and protein levels, increased ATF3 mRNA and protein and ATGL mRNA levels, and increased levels of phosphorylated AMP-activated protein kinase (AMPK) and protein kinase A (PKA). These findings suggest that ST32db may exert protective effects against MASLD through activating hepatic AMPK and PKA pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 23142, Taiwan.
- Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan.
- Department of Pediatrics, Tzu Chi University, Hualien 97004, Taiwan.
ORCID-Profile: Ching-Feng Cheng, Ruey-Bing Yang, Hui-Chen Ku
Förderung
- National Science and Technology Council
- Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
- the collaborative grants from the Tzu Chi Medical Foundation, the Tzu Chi University, and Ac-ademia Sinica
- National Science and Technology Council, Taiwan
- Taipei Tzu Chi Hospital; Buddhist Tzu Chi Medical Foundation, Taiwan
- Tzu Chi Medical Foundation, the Tzu Chi University, and Academia Sinica
Zitieren
APA
Cheng, C. F., Yang, R. B., Chen, W. T., Chung, J. F., & Ku, H. C. (2025). An ATF3 Inducer Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease Through the AMPK and PKA Pathways. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262411877
Vancouver
Cheng CF, Yang RB, Chen WT, Chung JF, Ku HC. An ATF3 Inducer Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease Through the AMPK and PKA Pathways. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262411877
BibTeX
@article{Cheng2025,
author = {Cheng, Ching-Feng and Yang, Ruey-Bing and Chen, Wen-Ting and Chung, Jia-Fang and Ku, Hui-Chen},
title = {An ATF3 Inducer Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease Through the AMPK and PKA Pathways},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262411877}
}
EUVIMED